Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada

Launched by PERIPHARM · Jun 16, 2025

Keywords

ClinConnect Summary

This is a Canadian, observational study designed to understand how platinum-resistant ovarian cancer affects a patient’s quality of life and the burden it places on caregivers. About 150 people are expected to participate, including adults with this cancer and the caregivers who support them. Participants will complete questionnaires at the time they join to measure the patient’s quality of life (using FACT-O and EQ-5D-5L), symptoms, caregiver quality of life (CarGOQoL), work and activity impairment (WPAI), and a questionnaire on treatment preferences. There is no treatment or intervention involved.

To be eligible, patients must be 18 or older with platinum-resistant ovarian cancer — meaning the cancer recurred within 6 months after last platinum chemotherapy and they have had more than one prior line of therapy — and must be able to read English or French and give consent. Exclusions include platinum-sensitive or platinum-refractory disease. Caregivers must also be 18+ and actively caring for a PROC patient identified through the Ovarian Cancer Canada mailing list, with the ability to read English or French and provide consent. The study will enroll participants in Montreal (PROxy Network) and is led by PeriPharm; data are collected at enrollment and will not involve any experimental treatment or drug, and individual data will not be shared publicly.

Gender

ALL

Eligibility criteria

• • Patient Inclusion Criteria
• • 1. ≥18 years old
• • 2. Patients with PROC who received \>1 prior line of therapy identified through a screening survey. PROC will be defined as recurrence less than 6 months after last platinum chemotherapy (i.e. carboplatin or cisplatin)
• • 3. Ability to read and understand French or English
• • 4. Signature of ICF
• • Patients Exclusion Criteria
• 1. Patients with PSOC, defined as those who:
• • 1. Have not progressed within less than 6 months after completion of platinum-based chemotherapy or;
• • 2. Are still on platinum chemotherapy or;
• • 3. Receive maintenance therapy.
• • 2. Patients with platinum-refractory ovarian cancer, defined as not responding or disease progressing during therapy or within three months after the last dose
• Caregivers Inclusion Criteria:
• • 1. ≥18 years old
• • 2. Current caregiver of a patient with PROC (see definition to be used above) who received \>1 prior line of therapy identified through a screening survey.
• • 3. Ability to read and understand French or English
• • 4. Signature of ICF.
• Caregivers Exclusion Criteria:
• • 1. Caregivers of patients with PSOC (see definition above)
• • 2. Caregivers of PROC patients who have passed away
• • 3. Caregivers of platinum-refractory patients (see definition above)